Apollomics Inc.
APLM, APLMW · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D53gen composite 24pct→53
Notable findings
- Going concernBased on our evaluation of conditions and events as of December 31, 2025, management has determined that substantial doubt exists about the Company’s ability to continue as a going concern
- Cash burnNegative free cash flow (-28.8M)
- Trial readout soonUpcoming trial readout ~2027-01-31 — PHASE1/PHASE2 · Metastatic Non Small Cell Lung Cancer
Key metrics
Return on equity
-1107.3%
Return on assets
-411.2%
Debt / equity
0.0×
Current ratio
1.4×
Free cash flow
-$29M
Tangible book value
$3M
Cash & investments
$10M
Cash runway
1q
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| Chen Hung-Wen | Chief Executive Officer | — |
| Chen Yi-Kuei | Chief Operating Officer | — |
| LIN PETER KUAN-HOW | Chief Financial Officer | — |
| CHEN HONG-JUNG | Director | — |
| CHU YI-AN | Director | — |
| Huang Ya-Chi | Director | — |
| Jan Chen-Huan | Director | — |
| TSAI HSIEN-SHU | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Insider transactions · last 6 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-15 | LIN PETER KUAN-HOW | Option exercise | 10K | — |
| 2026-06-15 | LIN PETER KUAN-HOW | Tax withheld | 3.6K | $13.85 |
| 2026-06-15 | Chen Hung-Wen | Option exercise | 5.0K | — |
| 2026-06-15 | CHU YI-AN | Option exercise | 500 | — |
| 2026-06-15 | CHEN HONG-JUNG | Option exercise | 500 | — |
| 2026-06-15 | TSAI HSIEN-SHU | Option exercise | 500 | — |
| 2026-06-15 | Chen Yi-Kuei | Option exercise | 5.0K | — |
| 2026-06-15 | Jan Chen-Huan | Option exercise | 500 | — |
| 2026-05-17 | Huang Ya-Chi | Option exercise | 500 | — |
| 2026-03-31 | LIN PETER KUAN-HOW | Tax withheld | 3.6K | $15.85 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04743505 ↗ | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Metastatic Non Small Cell Lung Cancer | PHASE1/PHASE2 | Active Not Recruiting | 2027-01-31 |
| NCT03175224 ↗ | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Solid Tumors, Advanced Cancer | PHASE2 | Recruiting | 2026-03-30 |
| NCT05055518 ↗ | APL-102 Capsule in Patients With Advanced Solid Tumors Advanced Solid Tumor | PHASE1 | Suspended | 2028-10-31 |
| NCT05054543 ↗ | Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML Relapsed/Refractory AML | PHASE3 | Terminated | 2024-08-22 |
| NCT04839341 ↗ | Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients Relapsed/Refractory AML | PHASE1 | Completed | 2024-06-28 |
| NCT05367388 ↗ | A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants Bioequivalence | PHASE1 | Unknown | 2022-11-01 |
| NCT03053466 ↗ | APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Solid Tumor, Microsatellite Instability | PHASE1 | Completed | 2022-02-25 |
| NCT03655613 ↗ | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Hepatocellular Carcinoma, Renal Cell Carcinoma | PHASE1/PHASE2 | Terminated | 2021-12-15 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-04-24 | 2025-12-31 | 0001193125-26-177357 ↗ |
| 20-F | 2025-04-03 | 2024-12-31 | 0000950170-25-050531 ↗ |
| 20-F | 2024-03-28 | 2023-12-31 | 0000950170-24-038107 ↗ |
| 20-F | 2023-04-28 | 2022-12-31 | 0001193125-23-127602 ↗ |
| 20-F | 2023-03-31 | 2023-03-29 | 0001193125-23-088218 ↗ |